Esophagectomy is the standard curative-intent operation for resectable Esophageal Cancer, and it also treats high-grade dysplasia or early (intramucosal/submucosal) cancer that cannot be eradicated endoscopically, end-stage Achalasia, and certain benign conditions such as esophageal perforation or a failed prior reflux or weight-loss operation (Aaron et al., American College of Surgeons, 2021; Ghosh et al., Gastrointestinal Oncology — A Critical Multidisciplinary Team Approach 2e, 2024). Although esophageal cancer accounts for only about 1% of new cancer diagnoses, it carries a disproportionately high mortality, which is why timely, well-planned surgical treatment matters (Aaron et al., 2021).

The operation involves removing a major length of the esophagus — typically with the adjacent lymph nodes — and reconstructing the swallowing tract, most commonly by shaping the stomach into a narrow "gastric conduit" and advancing it into the chest or neck to connect to the remaining esophagus (Xie, Smyth & Lagergren, New England Journal of Medicine, 2026; Ghosh et al., 2024). Because the esophagus passes through the neck, chest, and abdomen, the surgery requires access to more than one body cavity, which is what makes it technically demanding (Shah et al., Nature Reviews Clinical Oncology, 2023).

For most patients with locally advanced disease, esophagectomy is one part of a multimodality plan that includes chemotherapy or chemoradiation before (and sometimes after) surgery, coordinated by a multidisciplinary team (Shah et al., ASCO Guideline, 2020; NCCN, Esophageal and Esophagogastric Junction Cancers, 2026). Survival has improved substantially in recent years — U.S. five-year survival has risen to roughly 21.6% overall and is far higher for early-stage disease — driven by earlier detection through Barrett esophagus surveillance, better systemic therapy, and lower surgical morbidity (Molena et al., AATS Expert Consensus, 2025).

Esophagectomy restores the ability to swallow after the diseased esophagus is removed by creating a new conduit between the throat and the stomach. In the great majority of cases, the stomach itself is mobilized, divided with a stapler along its length into a tube that preserves its blood supply, and then brought up through the chest to be joined (anastomosed) to the remaining upper esophagus; when the stomach cannot be used, the colon or small bowel (jejunum) serves as the conduit (Xie, Smyth & Lagergren, New England Journal of Medicine, 2026; Ghosh et al., 2024; NCCN, 2026).

Removing the regional lymph nodes at the same time (lymphadenectomy) allows accurate staging and may improve outcomes in selected patients; guidelines recommend harvesting and assessing at least 16 lymph nodes for adequate staging in patients who go straight to surgery (NCCN, 2026; Xie, Smyth & Lagergren, 2026).

• Best chance of cure for localized esophageal cancer — complete (R0) resection with lymphadenectomy is the cornerstone of curative treatment for resectable disease (Ilson & van Hillegersberg, Gastroenterology, 2018; Aaron et al., 2021).

• Definitive treatment for dysplasia/early cancer not controllable endoscopically — removes the at-risk tissue entirely when endoscopic resection and ablation cannot (Ghosh et al., 2024; NCCN, 2026).

• Accurate pathologic staging — the resected specimen and lymph nodes guide any further therapy and prognosis (NCCN, 2026).

• Lower short-term morbidity with minimally invasive and robotic approaches — compared with open surgery, minimally invasive esophagectomy reduces pulmonary complications, wound infections, and length of stay without compromising long-term survival (Xie, Smyth & Lagergren, 2026; Guo et al., Surgical Endoscopy, 2016; Kuppusamy & Low, Annals of Surgery, 2022).

Esophagectomy is considered for patients who are physiologically fit for a major operation and who have (NCCN, 2026; Ghosh et al., 2024):

• Resectable esophageal or esophagogastric junction cancer — generally tumors invading the submucosa (T1b) or deeper, and locally advanced tumors (through T4a, with or without regional nodes) treated as part of a multimodality plan.

• Early (T1a) cancer with high-risk features — such as poor differentiation or lymphovascular invasion, or a positive deep margin after endoscopic resection.

• High-grade dysplasia that cannot be eradicated endoscopically (rare; every effort is first made to preserve the esophagus).

• Selected benign disease — end-stage achalasia, esophageal perforation, caustic injury, or a failed prior foregut/bariatric operation (Aaron et al., 2021).

Candidacy requires clinical staging with CT of the chest/abdomen, whole-body FDG-PET (PET/CT preferred), and endoscopic ultrasound, plus assessment of cardiopulmonary and nutritional fitness by an esophageal surgeon before any therapy begins (NCCN, 2026). Patients with unresectable disease (e.g., T4b invasion of the heart, great vessels, trachea, or distant metastases) are not surgical candidates and are directed to definitive chemoradiation or systemic therapy (NCCN, 2026).

‍

The approach is tailored to tumor location, the chosen conduit, and surgeon experience; all acceptable techniques yield broadly similar long-term survival, so selection is individualized (NCCN, 2026; Pennathur et al., Lancet, 2013). The main approaches are:

• Ivor Lewis (transthoracic) esophagectomy — an abdominal stage to create the gastric conduit plus a right chest stage with an anastomosis inside the chest. It is the most commonly performed approach worldwide and gives excellent exposure for intrathoracic lymphadenectomy (Shah et al., 2023; Ghosh et al., 2024).

• McKeown (tri-incisional) esophagectomy — chest, abdomen, and a left neck incision with the anastomosis in the neck; favored for more proximal tumors (Spechler, Wang & Souza, Yamada's Textbook of Gastroenterology 7e, 2022; Ghosh et al., 2024).

• Transhiatal esophagectomy — abdominal and left neck incisions with dissection through the diaphragmatic hiatus, avoiding a thoracotomy; associated with lower pulmonary morbidity but a less complete mediastinal lymphadenectomy, useful in frailer patients or selected junctional tumors (Shah et al., 2023; Ghosh et al., 2024; Apostoloska et al., Anaesthesia and Intensive Care, 2026).

• Minimally invasive and robotic esophagectomy — laparoscopic/thoracoscopic or robotic versions of the above, now the most common approach and strongly encouraged by guidelines for their improved recovery (NCCN, 2026; Aaron et al., 2021). A feeding jejunostomy is generally placed for postoperative nutrition (NCCN, 2026).

Esophagectomy carries a meaningful complication rate even in expert hands — overall complications occur in roughly 59–65% of patients — so an honest understanding of the risks is essential (Low et al., Annals of Surgery, 2019; van der Werf et al., Annals of Surgery, 2020). The most important risks are:

• Pulmonary complications, including pneumonia (~14–21%) — the single biggest driver of postoperative death (Low et al., 2019; Goense et al., British Journal of Surgery, 2019).

• Anastomotic leak (~11–13%) — leak from the new connection; the second-largest contributor to mortality and reoperation, and intrathoracic leaks can be especially dangerous (Low et al., 2019; Goense et al., 2019).

• Atrial dysrhythmia (~14–15%), chyle leak (~4.7%), recurrent laryngeal nerve injury causing hoarseness (~4.2%), and conduit necrosis (~1.3%) (Low et al., 2019; Chevallay et al., Annals of the New York Academy of Sciences, 2020).

• Perioperative mortality — approximately 2–2.4% at 30 days and ~4.5% at 90 days in high-volume international series, but substantially higher at low-volume centers (Low et al., 2019; Kuppusamy & Low, 2022; Aaron et al., 2021).

Because pulmonary complications and anastomotic leak dominate the risk profile, prevention and early recognition of these two complications have the greatest impact on survival (Goense et al., 2019).

Recovery is staged and deliberate. Patients typically spend the initial days in a monitored or intensive-care setting, with early mobilization, pulmonary care to prevent pneumonia, and nutrition delivered through the feeding jejunostomy until the anastomosis has healed and swallowing is safely resumed (NCCN, 2026; Apostoloska et al., Anaesthesia and Intensive Care, 2026). A contrast study is often used before starting oral intake to confirm the anastomosis is intact. Minimally invasive and robotic approaches shorten hospital stay and speed functional recovery compared with open surgery (Xie, Smyth & Lagergren, 2026; Guo et al., 2016). Full recovery of eating, weight, and energy unfolds over several months as patients adapt to smaller, more frequent meals.

With complete resection, long-term outcomes have improved markedly, and early-stage disease carries a favorable prognosis; U.S. five-year survival for esophageal cancer overall is now about 21.6% and considerably higher when caught early (Molena et al., AATS Expert Consensus, 2025). Over the long term, most patients return to an oral diet but adapt to permanent changes in how they eat — smaller portions, upright posture during and after meals, and attention to reflux (see below). Ongoing oncologic surveillance and nutritional follow-up remain part of long-term care (NCCN, 2026).

Esophageal disease requiring resection almost always begins upstream — with reflux, Barrett esophagus, and dysplasia — which is precisely the foregut pathway Dr. de la Cruz-Muñoz evaluates and manages. As a board-certified metabolic and foregut surgeon, he provides comprehensive evaluation of the esophagus and stomach, including the endoscopic, manometric, and pH assessment that detects disease early, when it is most treatable and often curable by endoscopic means before an esophagectomy is ever needed. For patients who do require resection, the most important determinant of a safe outcome is that the operation and the full multimodality plan are delivered through an experienced, high-volume esophageal program with critical-care support — a standard supported by the strongest outcome data (Aaron et al., 2021; Xie, Smyth & Lagergren, 2026). Dr. de la Cruz-Muñoz coordinates that multidisciplinary pathway — surgical oncology, medical oncology, radiation oncology, and nutrition — so that each patient is matched to the right treatment, at the right center, at the right time.

Not applicable. Esophagectomy is a cancer/foregut operation, not a weight-loss procedure, and is never performed to produce weight loss. In fact, unintended weight loss is a common postoperative challenge, which is why nutritional support (below) is a central part of recovery rather than a goal (NCCN, 2026).

‍

Not applicable in the bariatric sense — esophagectomy is not a metabolic operation and is not expected to produce diabetes remission or the metabolic benefits seen after weight-loss surgery. The "benefit" of this operation is oncologic: cure or control of esophageal cancer and removal of premalignant tissue (Ilson & van Hillegersberg, 2018).

‍

‍

Not applicable. This field pertains to weight-loss surgery. For esophagectomy patients the relevant concern is the opposite — preventing excessive weight loss and malnutrition through structured nutritional support and long-term dietary follow-up (NCCN, 2026).

‍

Reflux is a genuine and expected long-term issue after esophagectomy. When the stomach is reconfigured as a conduit and the normal antireflux barrier is removed, acid and bile reflux and regurgitation are common, and patients are counseled on upright posture after meals, smaller meals, not eating close to bedtime, and acid-suppression medication as needed (Apostoloska et al., Anaesthesia and Intensive Care, 2026). This is distinct from the reflux-reduction goals of bariatric procedures and should be set as a realistic expectation before surgery.

‍

As a medically necessary cancer operation, esophagectomy is covered when indicated, and qualification is driven by oncologic criteria rather than BMI or the supervised-diet requirements of bariatric surgery. Insurers require documentation of the diagnosis and clinical stage (biopsy/pathology, CT, PET/CT, EUS), multidisciplinary tumor-board review, and confirmation of surgical fitness (NCCN, 2026). Coverage and outcomes both favor care at accredited, high-volume esophageal centers.

• Complete staging — CT chest/abdomen, PET/CT, EUS, and diagnostic endoscopy with biopsy (NCCN, 2026).

• Multidisciplinary review and completion of any planned neoadjuvant chemotherapy or chemoradiation before surgery (Shah et al., ASCO Guideline, 2020).

• Cardiopulmonary assessment and prehabilitation — optimizing lung function, physical conditioning, and smoking cessation to reduce pulmonary complications (Apostoloska et al., 2026).

• Nutritional optimization — correcting malnutrition beforehand; for patients who cannot swallow adequately during induction therapy, a feeding jejunostomy or esophageal dilation is preferred over a gastrostomy, which can compromise the future gastric conduit (NCCN, 2026).

‍

Nutrition is a cornerstone of recovery. Enteral feeding through the jejunostomy tube typically bridges the period until the anastomosis heals and oral intake is confirmed safe; patients then transition gradually to small, frequent, protein-rich meals eaten slowly and upright (NCCN, 2026; Apostoloska et al., 2026). Dumping-type symptoms and early satiety are common with a gastric conduit and are managed with dietary pacing and composition adjustments. Long-term dietitian follow-up helps restore and maintain weight.

‍

Early and progressive mobilization begins in the hospital and is central to preventing pulmonary complications and blood clots (Apostoloska et al., 2026). Activity is advanced gradually over the following weeks, with a focus on walking, breathing exercises, and rebuilding strength to counter the muscle loss that accompanies major surgery and significant weight loss; heavy lifting and strenuous activity are deferred until cleared by the surgical team.

‍